{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T08:28:34Z","timestamp":1763368114962,"version":"3.45.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.prp.2025.156278","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T16:55:08Z","timestamp":1762361708000},"page":"156278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["PTEN mutation status in uterine carcinosarcomas: A comprehensive overview and a new diagnostic approach"],"prefix":"10.1016","volume":"276","author":[{"given":"Maccio","family":"Livia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bragantini","family":"Emma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piermattei","family":"Alessia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santoro","family":"Angela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zannoni Gian","family":"Franco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.prp.2025.156278_bib1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/ijgc-2022-004073","article-title":"Endometrial carcinosarcoma","volume":"33","author":"Bogani","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"11","key":"10.1016\/j.prp.2025.156278_bib2","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/PAS.0b013e3181161ba3","article-title":"Prognostic features of surgical stage I uterine carcinosarcoma","volume":"31","author":"Ferguson","year":"2007","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2025.156278_bib3","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/1097-0142(19800401)45:7<1625::AID-CNCR2820450718>3.0.CO;2-A","article-title":", Postirradiation mixed m\u00fcllerian tumors of the uterus: a comparative clinicopathologic study","volume":"45","author":"Varela-Duran","year":"1980","journal-title":"Cancer"},{"key":"10.1016\/j.prp.2025.156278_bib4","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1046\/j.1525-1438.1995.05040310.x","article-title":"Is there an association between long-term tamoxifen treatment and the development of carcinosarcoma (malignant mixed m\u00fcllerian tumor) of the uterus?","volume":"5","author":"Evans","year":"1995","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"7","key":"10.1016\/j.prp.2025.156278_bib5","doi-asserted-by":"crossref","first-page":"964","DOI":"10.3390\/cancers11070964","article-title":"Molecular basis of tumor heterogeneity in endometrial carcinosarcoma","volume":"11","author":"Leskela","year":"2019","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.prp.2025.156278_bib6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ccell.2017.02.010","article-title":"Integrated molecular characterization of uterine carcinosarcoma","volume":"31","author":"AD Cherniack","year":"2017","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.prp.2025.156278_bib7","doi-asserted-by":"crossref","first-page":"5765","DOI":"10.21873\/anticanres.11160","article-title":"Targeting the PI3K\/PTEN\/AKT\/mTOR pathway in treatment of sarcoma cell lines","volume":"36","author":"Lim","year":"2016","journal-title":"Anticancer Res."},{"issue":"7","key":"10.1016\/j.prp.2025.156278_bib8","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3390\/genes11070719","article-title":"PTEN alterations and their role in cancer management: are we making headway on precision medicine?","volume":"11","author":"Fusco","year":"2020","journal-title":"Genes"},{"issue":"1","key":"10.1016\/j.prp.2025.156278_bib9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1006\/gyno.2002.6601","article-title":"PTEN mutations in uterine sarcomas","volume":"85","author":"Amant","year":"2002","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.prp.2025.156278_bib10","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3390\/cancers11101458","article-title":"PTEN and gynecological cancers","volume":"11","author":"Nero","year":"2019","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.prp.2025.156278_bib11","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3390\/cancers11040435","article-title":"PTEN as a prognostic\/predictive biomarker in cancer: an unfulfilled promise?","volume":"11","author":"Ciuffreda","year":"2019","journal-title":"Cancers"},{"issue":"14","key":"10.1016\/j.prp.2025.156278_bib12","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-19-3959","article-title":"Genomic landscape of uterine sarcomas defined through prospective clinical sequencing","volume":"26","author":"Hensley","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2025.156278_bib13","article-title":"Uterine carcinosarcoma: a case report and literature review","volume":"20","author":"Kord","year":"2020","journal-title":"Case Rep. Obstet. Gynecol."},{"key":"10.1016\/j.prp.2025.156278_bib14","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1038\/s41598-023-31759-6","article-title":"Pan-cancer genomic analysis shows hemizygous PTEN loss tumors are associated with immune evasion and poor outcome","volume":"13","author":"Vidotto","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2025.156278_bib15","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"issue":"5","key":"10.1016\/j.prp.2025.156278_bib16","first-page":"456","article-title":"Advances in synthetic lethality for PTEN-deficient tumors","volume":"83","author":"Vonn","year":"2023","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.prp.2025.156278_bib17","first-page":"2159","article-title":"Mechanistic rationale to target PTEN-deficient cancers with PARP inhibitors","volume":"21","author":"Johnson","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.prp.2025.156278_bib18","first-page":"234","article-title":"Microsatellite instability and PTEN loss in endometrial cancers","volume":"22","author":"Taylor","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.prp.2025.156278_bib19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11515-017-1443-5","article-title":"PTEN at the interface of immune tolerance and tumor suppression","volume":"12","author":"Brandmaier","year":"2017","journal-title":"Front. Biol."},{"issue":"6","key":"10.1016\/j.prp.2025.156278_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2020.152943","article-title":"PTEN mutation: A potential prognostic factor associated with immune infiltration in endometrial carcinoma","volume":"216","author":"Tao","year":"2020","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.prp.2025.156278_bib21","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.it.2004.09.015","article-title":"The chemokine system in diverse forms of macrophage activation and polarization","volume":"25","author":"Mantovani","year":"2004","journal-title":"Trends Immunol."},{"key":"10.1016\/j.prp.2025.156278_bib22","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/15384047.2014.1002353","article-title":"PTEN inhibits macrophage polarization from M1 to M2 through CCL2 and VEGF-A reduction and NHERF-1 synergism","volume":"16","author":"Li","year":"2015","journal-title":"Cancer Biol. Ther."},{"issue":"11","key":"10.1016\/j.prp.2025.156278_bib23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11864-015-0370-4","article-title":"Review of recommended treatment of uterine carcinosarcoma","volume":"16","author":"Menczer","year":"2015","journal-title":"Curr. Treat. Options Oncol."},{"issue":"1","key":"10.1016\/j.prp.2025.156278_bib24","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/modpathol.2015.137","article-title":"A practical approach to the diagnosis of mixed epithelial and mesenchymal tumours of the uterus","volume":"29","author":"McCluggage","year":"2016","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.prp.2025.156278_bib25","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/jmri.25981","article-title":"Diagnostic accuracy of 3.0T diffusion-weighted MRI for patients with uterine carcinosarcoma: assessment of tumor extent and lymphatic metastasis","volume":"48","author":"Huang","year":"2018","journal-title":"Magn. Reson. Imaging"},{"key":"10.1016\/j.prp.2025.156278_bib26","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ygyno.2012.11.025","article-title":"MRI, PET\/CT and ultrasound in the preoperative staging of endometrial cancer \u2014 a multicenter prospective comparative study","volume":"128","author":"Antonsen","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.prp.2025.156278_bib27","first-page":"345","article-title":"Tumor heterogeneity in carcinosarcomas: challenges for targeted therapies","volume":"12","author":"Wilson","year":"2021","journal-title":"Cancer Genom."},{"issue":"6","key":"10.1016\/j.prp.2025.156278_bib28","article-title":"Molecular subtypes of endometrial cancer: implications for adjuvant treatment strategies","volume":"34","author":"Yang","year":"2023","journal-title":"J. Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.prp.2025.156278_bib29","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.3390\/jcm12083014","article-title":"Could inhibiting the DNA damage repair checkpoint rescue immune-checkpoint-inhibitor-resistant endometrial cancer?","volume":"12","author":"Li","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.prp.2025.156278_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-78646-y","article-title":"Combination treatment with a PI3K\/Akt\/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells","volume":"10","author":"Fujimoto","year":"2020","journal-title":"Sci. Rep."},{"issue":"19","key":"10.1016\/j.prp.2025.156278_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914960","article-title":"Unveiling novel avenues in mTOR-targeted therapeutics: advancements in glioblastoma treatment","volume":"24","author":"Singh","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.prp.2025.156278_bib32","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1158\/2326-6066.CIR-15-0252","article-title":"Enhanced tumor control with combination mTOR and PD-L1 inhibition in syngeneic oral cavity cancers","volume":"4","author":"Moore","year":"2016","journal-title":"Cancer Immunol. Res"},{"issue":"7","key":"10.1016\/j.prp.2025.156278_bib33","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/nrd.2016.134","article-title":"Bivalent mTOR inhibitors \u2014 the next generation","volume":"15","author":"Flemming","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"issue":"26","key":"10.1016\/j.prp.2025.156278_bib34","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer","volume":"38","author":"Makker","year":"2020","journal-title":"J. Clin. Oncol."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825004716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825004716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T08:23:41Z","timestamp":1763367821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033825004716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":34,"alternative-id":["S0344033825004716"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2025.156278","relation":{},"ISSN":["0344-0338"],"issn-type":[{"type":"print","value":"0344-0338"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PTEN mutation status in uterine carcinosarcomas: A comprehensive overview and a new diagnostic approach","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2025.156278","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156278"}}